Context Therapeutics Inc. (CNTX)
NASDAQ: CNTX · Real-Time Price · USD
0.4592
-0.0066 (-1.42%)
Aug 12, 2026, 11:05 AM EDT - Market open
Context Therapeutics Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Context Therapeutics stock has a consensus rating of "Buy" and an average price target of $4.25. The average 1-year stock price forecast is 825.52% higher than the current stock price, while the lowest is $2.00 (+335.54%) and the highest is $6.00 (+1,206.62%).
Price Target: $4.25 (+825.52%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Context Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 6 | 7 | 6 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Buy Maintains $4 | Buy | Maintains | $4 | +771.08% | Aug 11, 2026 |
| LifeSci Capital | LifeSci Capital | Hold Downgrades $2 | Hold | Downgrades | $2 | +335.54% | Aug 6, 2026 |
| Citizens JMP | Citizens JMP | Buy Maintains $4 → $3 | Buy | Maintains | $4 → $3 | +553.31% | Aug 6, 2026 |
| William Blair | William Blair | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Aug 6, 2026 |
| JonesTrading | JonesTrading | Buy Reiterates $7 → $2 | Buy | Reiterates | $7 → $2 | +335.54% | Aug 6, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.44
from -0.38
EPS Next Year
-0.41
from -0.44
EPS and Forward PE are based on non-GAAP adjusted numbers.